In conclusion, we show here that a sizable fraction of DLBCL patients, especially of the ABC subtype, exhibit hallmarks of aberrant activation of the IL‐6 signaling pathway which constitutes a promising therapeutic target in this population. The gene discussed is IL6; the disease is aneurysmal bone cyst.